MMS Insights
webinar
September 26th, 2024
Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance
webinar
September 12th, 2024
No Stone Unturned: Optimizing the Use of Expedited Pathways and Oncology Center of Excellence Programs to Optimize Drug Development in Oncology
regulatory intelligence
August 27th, 2024
Recent Guidance on Diversity Action Planning
regulatory intelligence
August 26th, 2024
Oncology Programs at the FDA
regulatory intelligence
August 26th, 2024
Three Key Take Reflections on the Recent Donanemab Approval
regulatory intelligence
August 9th, 2024
FDA Updates 2024 Language Access Plan
regulatory intelligence
August 3rd, 2024
EMA Launches New Pilot Program for Orphan Medical Devices
perspectives
July 30th, 2024
The Critical Role of Quality Control (QC) – Medical Writing and Beyond
regulatory intelligence
July 26th, 2024
Key Decision Points for Recent Oncology Approvals
regulatory intelligence
July 24th, 2024
Comments Open for Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products
perspectives
July 23rd, 2024
PSI 2024 Ignited Conversations on External Data Sources, Requirements for Estimands, and Bayesian Methodology for Statisticians in Pharma
news
July 17th, 2024
Industry Veteran Ben Dudley Joins MMS as Chief Commercial Officer (CCO) to Drive Continued Growth for the Data-focused Clinical Research Organization